Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs. The NF-kB protein plays a critical role in the inflammatory response and is activated by e.g. TNF, which is produced by the white blood cells.

Read the full story here

ConvaTec has announced the launch in Canada of a new web site, www.Hydrofiber.ca, demonstrating how the company’s proprietary Hydrofiber(R) Technology is transforming wound care. Designed for clinicians managing chronic and acute wounds, the web site illustrates the unique features and benefits of Hydrofiber(R) Technology with extensive video, data and commentary from research scientists within ConvaTec Wound Therapeutics. This transformational technology, unique to ConvaTec, powers the performance of advanced wound care products.

For the full story, Click Here

“410B,” a new style of breast implant, could reduce healing time and ease pain. Although it is not yet approved by the FDA, the plastic surgeon who created it calls it the “most studied breast implant ever.” Also known as the ‘Gummy Bear Implant,’ the product is the only implant in history that stimulated the development of techniques that let people recover in 24 hours and go out for dinner on the night of surgery, Plastic Surgeon John Tebbetts said proudly.

Light BioScience LLC has received a 510(k) over-the-counter (OTC) clearance from the FDA for its GentleWaves LED Photomodulation technology. The LED (light emitting diode) based, anti-wrinkle treatment is already being used by physicians to reduce the appearance of fine lines and wrinkles. The company claims that the technology helps to stimulate collagen production as well as to slow down collagen breakdown. Light BioScience can now develop a device that can be sold without a prescription.